David Holladay, MD
Radiation Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
University of Alabama
Medical School
University of Alabama Medical Center
Internship
Indiana University
Residency
American Board of Radiology - Radiation Oncology
GA State Medical License: 1990 - 2019
AL State Medical License: 1987 - 2013
American Board of Radiology: Radiation Oncology
DeKalb Medical at North Decatur
Languages: English/Spanish
+1 404-501-1000
2701 N Decatur Rd
Read More32 citations Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer.
Critz, F. A., Levinson, K., Williams, W. H., Holladay, D., Holladay, C., Griffin, V.; Urology. 1997 May.
See more >>145 citations Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer.
Critz, F. A., Williams, W. H., Benton, J. B., Levinson, A. K., Holladay, C. T., Holladay, D. A.; J Urol. 2000 Apr.
See more >>Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques.
Critz, F. A., Williams, W. H., Holladay, C. T., Levinson, A. K., Benton, J. B., Holladay, D. A., Schnell, F. J., Maxa, L. S., Shrake, P. D.; Urology. 1999 Dec.
See more >>